Triple negative breast cancer: Unmet medical needs

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 627-636

  Pal, Sumanta Kumar ^a   Childs, Barrett H ^b   Pegram, Mark ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like; BRCA1; Breast cancer; Phenotype; Targeted therapy; Triple negative

Indexed keywords

4 IODO 3 NITROBENZAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IXABEPILONE; NAVELBINE; OLAPARIB; PACLITAXEL; PANITUMUMAB; PF 01367338; PROGESTERONE RECEPTOR; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE SEVERITY; DNA MICROARRAY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEARING LOSS; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; MAMMOGRAPHY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TINNITUS; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; HUMANS; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 79151476662     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1293-1     Document Type: Review

References (71)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. CM Perou T Sørlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
3. T Sørlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein LP Eystein AL Borresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
4. T Sørlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler J Demeter CM Perou PE Lonning PO Brown AL Borresen-Dale D Botstein 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
5. BT Hennessy AM Gonzalez-Angulo K Stemke-Hale MZ Gilcrease S Krishnamurthy JS Lee J Fridlyand A Sahin R Agarwal C Joy W Liu D Stivers K Baggerly M Carey A Lluch C Monteagudo X He V Weigman C Fan J Palazzo GN Hortobagyi LK Nolden NJ Wang V Valero JW Gray CM Perou GB Mills 2009 Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics Cancer Res 69 4116 4124 1:CAS:528: DC%2BD1MXlvFWltrg%3D 10.1158/0008-5472.CAN-08-3441 19435916
6. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929138/?tool= pubmed. Accessed 29 July 2010
7. AA Onitílo JM Engel RT Greenlee BN Mukesh 2009 Breast cancer subtypes based on ER/PR and HER2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 4 13 10.3121/cmr.2009.825 19574486
8. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry Cancer 109 1721 1728 10.1002/cncr.22618 17387718 (Pubitemid 46668532)
9. EA Rakha ME El-Sayed AR Green AHS Lee JF Robertson IO Ellis 2007 Prognostic markers in triple-negative breast cancer Cancer 109 25 32 1:CAS:528:DC%2BD2sXhtVKrtLY%3D 10.1002/cncr.22381 17146782 (Pubitemid 46120191)
10. H Tsuda T Takarabe F Hasegawa T Fukutomi S Hirohashi 2000 Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases Am J Surg Pathol 24 197 202 1:STN:280:DC%2BD3c7ktlWhsA%3D%3D 10.1097/00000478-200002000-00005 10680887 (Pubitemid 30078708)
11. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Narod 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR- 06-3045 17671126 (Pubitemid 47219710)
12. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas L Harris W Hait D Toppmeyer 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652 5657 10.1200/JCO.2006.06.5664 17116942 (Pubitemid 46631305)
13. GJ Morris S Naidu AK Topham F Guiles Y Xu P McCue GF Schwartz PK Park AL Rosenberg K Brill EP Mitchell 2007 Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results Database Cancer 110 876 884 10.1002/cncr.22836 17620276 (Pubitemid 47257667)
14. ME Hammond DF Hayes M Dowsett DC Allred KL Hagerty S Badve PL Fitzgibbons G Francis NS Goldstein M Hayes DG Hicks S Lester R Love PB Mangu L McShane K Miller CK Osborne S Paik J Perlmutter A Rhodes H Sasano JN Schwartz FCG Sweep S Taube EE Torlakovic P Valenstein G Viale D Visscher T Wheeler RB Williams JL Wittliff AC Wolff 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784 2795 10.1200/JCO.2009.25.6529 20404251
15. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
16. CA Parise KR Bauer MM Brown V Caggiano 2009 Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004 Breast J 15 593 602 10.1111/j.1524-4741.2009. 00822.x 19764994
17. J Hugh J Hanson MCU Cheang TO Nielsen CM Perou C Dumontet J Reed M Krajewska I Treilleux M Rupin E Magherini J Mackey M Martin C Vogel 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 1168 1176 1:CAS:528:DC%2BD1MXktFKhs7Y%3D 10.1200/JCO.2008.18.1024 19204205
18. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 1:CAS:528:DC%2BD2sXkt1enur0%3D 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
19. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L (2006) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8:R66. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797029/. Accessed 29 July 2010
20. WD Foulkes J-B Brunet IM Stefansson O Straume PO Chappuis LR Begin N Hamel JR Goffin N Wong M Trudel L Kapusta P Porter LA Akslen 2004 The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835 1:CAS:528:DC%2BD2cXhtFCgtLo%3D 10.1158/0008-5472.CAN-03-2970 14871808 (Pubitemid 38176880)
21. WD Foulkes IM Stefansson PO Chappuis LR Bégin JR Goffin N Wong M Trudel LA Akslen 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 1482 1485 1:CAS:528:DC%2BD3sXnvVCjtrk%3D 14519755
22. Tischkowitz M, Brunet J-S, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948892/pdf/1471-2407-7-134.pdf. Accessed 29 July 2010
23. J Jacquemier L Padovani L Rabayrol SR Lakhani F Penault-Llorca Y Denoux M Fiche P Figueiro V Maisongrosse V Ledoussal J Martinez Penuela N Udvarhely G El Makdissi C Ginestier J Geneix E Charafe-Jauffret L Xerri F Eisinger D Birnbaum H Sobol 2005 Typical medullary breast carcinomas have a basal/myoepithelial phenotype J Pathol 207 260 268 1:CAS:528:DC%2BD2MXht1agu7bI 10.1002/path.1845 16167361 (Pubitemid 41556449)
24. CA Livasy G Karaca R Nanda MS Tretiakova OI Olopade DT Moore CM Perou 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Mod Pathol 19 264 271 1:CAS:528:DC%2BD28Xlt1eqtw%3D%3D 10.1038/modpathol.3800528 16341146 (Pubitemid 43117611)
25. JS Reis-Filho F Milanezi D Steele K Savage PT Simpson JM Nesland EM Pereira SR Lakhani FC Schmitt 2006 Metaplastic breast carcinomas are basal-like tumours Histopathology 49 10 21 1:STN:280:DC%2BD28vitFOitA%3D%3D 10.1111/j.1365-2559.2006.02467.x 16842242 (Pubitemid 43972916)
26. S Cleator W Heller RC Coombes 2007 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235 244 10.1016/S1470-2045(07)70074-8 17329194 (Pubitemid 46291713)
27. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 1:CAS:528:DC%2BD2cXmvFSlt7k%3D 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
28. SK Pal J Mortimer 2009 Triple-negative breast cancer: novel therapies and new directions Maturitas 63 269 274 1:CAS:528:DC%2BD1MXpsF2itrs%3D 10.1016/j.maturitas.2009.06.010 19632796
29. JS Reis-Filho ANJ Tutt 2008 Triple negative tumors: a critical review Histopathology 52 108 118 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D 10.1111/j.1365-2559.2007.02889.x 18171422 (Pubitemid 350265179)
30. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8:R34. Available at http://www.ncbi.nlm.nih.gov/pubmed?term= %22Breast+Cancer+Res%22%5BJour%5D+AND+2006%5Bpdat%5D+AND+Calza%5Bauthor%5D& cmd=detailssearch. Accessed 29 July 2010
31. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, Isola J (2007) Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9:R16 Available at http://www.ncbi.nlm.nih. gov/pmc/articles/PMC1851391/. Accessed 29 July, 2010
32. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5684 1:CAS:528: DC%2BD2MXos1Cjs7k%3D 10.1158/1078-0432.CCR-04-2421 16115903 (Pubitemid 41170290)
33. C Sotiriou S-Y Neo LM McShane EL Korn PM Long A Jazaeri P Martiat SB Fox AL Harris ET Liu 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 10393 10398 1:CAS:528:DC%2BD3sXntFynsrk%3D 10.1073/pnas.1732912100 12917485 (Pubitemid 37071889)
34. S Nofech-Mozes M Trudeau HK Kahn R Dent E Rawlinson P Sun SA Narod WM Hanna 2009 Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers Breast Cancer Res Treat 118 131 137 10.1007/s10549-008-0295-8 19189211
35. M Robson 2000 Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer J Clin Oncol 18 113s 118s 1:CAS:528:DC%2BD3cXot1antLs%3D 11060338
36. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev 4 1 6
37. Y Miyoshi K Murase K Oh 2008 Basal-like subtype and BRCA1 dysfunction in breast cancers Int J Clin Oncol 13 395 400 1:CAS:528:DC%2BD1cXht1Oktr3P 10.1007/s10147-008-0831-x 18946749
38. NC Turner JS Reis-Filho 2006 Basal-like breast cancer and the BRCA1 phenotype Oncogene 25 5846 5853 1:CAS:528:DC%2BD28XhtVSgurjO 10.1038/sj.onc.1209876 16998499 (Pubitemid 44453440)
39. DP Atchley CT Albarracin A Lopez V Valero CI Amos AM Gonzalez-Angulo GN Hortobagyi BK Arun 2008 Clinical and pathological characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26 4282 4288 10.1200/JCO.2008.16.6231 18779615
40. DM Abd El-Rehim G Ball SE Pinder E Rakha C Paish JF Robertson D Macmillan RW Blamey IO Ellis 2005 High-throughput protein expression analysis using tissue microarray technology of a well-characterized series identifies biologically distinct classes of breast cancer confirming recent DNA expression analyses Int J Cancer 116 340 350 1:CAS:528:DC%2BD2MXmtl2ktb0%3D 10.1002/ijc.21004 15818618 (Pubitemid 40993329)
41. C Beger LN Pierce M Krüger EG Marcusson JM Robbins P Welcsh PJ Welch K Welte MC King JR Barber F Wong-Staal 2001 Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach Proc Natl Acad Sci USA 98 130 135 1:CAS:528:DC%2BD3MXkslKrsw%3D%3D 10.1073/pnas.98.1.130 11136250 (Pubitemid 32095875)
42. NC Turner JS Reis-Filho AM Russell RJ Springall K Ryder D Steele K Savage CE Gillett FC Schmitt A Ashworth AN Tutt 2007 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 2126 2132 1:CAS:528:DC%2BD2sXjsFSiu7c%3D 10.1038/sj.onc.1210014 17016441 (Pubitemid 46514749)
43. RC Millikan B Newman C-K Tse PG Moorman K Conway LG Dressler LV Smith MH Labbok J Geradts JT Bensen S Jackson S Nyante C Livasy L Carey HS Earp CM Perou 2008 Epidemiology of basal-like breast cancer Breast Cancer Res Treat 109 123 139 10.1007/s10549-007-9632-6 17578664 (Pubitemid 351538762)
44. XR Yang ME Sherman DL Rimm J Lissowska LA Brinton B Peplonska SM Hewitt WF Anderson N Szeszenia-Dabrowska A Bardin-Mikolajczak W Zatonski R Cartun D Mandich G Rymkiewicz M Ligaj S Lukaszek R Kordek M Garcia-Closas 2007 Differences in risk factors for breast cancer molecular subtypes in a population-based study Cancer Epidemiol Biomarkers Prev 16 439 443 1:CAS:528:DC%2BD2sXjt1Srt7s%3D 10.1158/1055-9965.EPI-06-0806 17372238 (Pubitemid 46548646)
45. K Collett IM Stefansson J Eide A Braaten H Wang GE Eide SO Thoresen WD Foulkes LA Akslen 2005 A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors Cancer Epidemiol Biomarkers Prev 14 1108 1112 1:CAS:528:DC%2BD2MXktFCksLg%3D 10.1158/1055-9965.EPI-04-0394 15894660 (Pubitemid 40656455)
46. National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in Oncology™. Breast cancer. V.1.2010. Available at http://www.nccn.org. Accessed 8 June 2010
47. BP Schneider EP Winer WD Foulkes J Garber CM Perou A Richardson GW Sledge LA Carey 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 8010 8018 1:CAS:528:DC%2BD1cXhsV2it73F 10.1158/1078-0432.CCR- 08-1208 19088017
48. DP Silver AL Richardson AC Eklund ZC Wang Z Szallasi Q Li N Juul CO Leong D Calogrias A Buraimoh A Fatima RS Gelman PD Ryan NM Tung A De Nicolo S Ganesan A Miron C Colin DC Sgroi LW Ellisen EP Winer JE Garber 2010 Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 1145 1153 1:CAS:528:DC%2BC3cXktF2ltLk%3D 10.1200/JCO.2009.22.4725 20100965
49. T Byrski J Gronwald T Huzarski E Grzybowska M Budryk M Stawicka T Mierzwa M Szwiec R Wisniowski M Siolek R Dent J Lubinski S Narod 2010 Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy J Clin Oncol 28 375 379 1:CAS:528:DC%2BC3cXivFart74%3D 10.1200/JCO.2008.20.7019 20008645
50. B Sirohi M Arnedos S Popat S Ashley A Nerurkar G Walsh S Johnston IE Smith 2008 Platinum-based chemotherapy in triple-negative breast cancer Ann Oncol 19 1847 1852 1:STN:280:DC%2BD1cnosVCqsQ%3D%3D 10.1093/annonc/mdn395 18567607
51. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia WF Symmans AM Gonzalez-Angulo B Hennessy M Green M Cristofanilli GN Hortobagyi L Pusztai 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
52. R Dent WM Hanna M Trudeau E Rawlinson P Sun SA Narod 2009 Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res Treat 115 423 428 10.1007/s10549-008-0086-2 18543098
53. I Patanaphan OM Salazar R Risco 1988 Breast cancer: metastatic patterns and their prognosis South Med J 81 1109 1112 1:STN:280:DyaL1czjs12nug%3D%3D 3420442
54. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D, Lakhani SR (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851397/. Accessed 29 July 2010
55. DG Hicks SM Short NL Prescott SM Tarr KA Coleman BJ Yoder JP Crowe TK Choueiri AE Dawson GT Budd RR Tubbs G Casey RJ Weil 2006 Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR Am J Surg Pathol 30 1097 1104 16931954
56. J Gaedcke F Traub S Milde L Wilkens A Stan H Ostertag M Christgen R von Wasielewski HH Kreipe 2007 Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer Mod Pathol 20 864 870 1:CAS:528: DC%2BD2sXnvVeks7Y%3D 10.1038/modpathol.3800830 17541441 (Pubitemid 47077270)
57. F Kassam K Enright R Dent G Dranitsaris J Myers C Flynn M Fralick R Kumar M Clemons 2009 Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clin Breast Cancer 9 29 33 10.3816/CBC.2009.n.005 19299237
58. N McCabe NC Turner CJ Lord K Kluzek A Bialkowska S Swift S Giavara MJ O'Connor AN Tutt MZ Zdzienicka GC Smith A Ashworth 2006 Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 8109 8115 1:CAS:528:DC%2BD28XotFWqtLg%3D 10.1158/0008-5472.CAN-06-0140 16912188 (Pubitemid 44299177)
59. O'Shaughnessy J, Osborne C, Pippen J (2009) Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC) (Abstract no. 3122). Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009. Available at http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L-998. Accessed 28 July 2010
60. Ossovskaya V, Li L, Broude EV, Lim C, Roninson IB, Bradley C, Sherman B (2009) BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer (Abstract no. 5552). Presented at the 2009 American Association for Cancer Research 100th Annual Meeting, Denver, Co, April 18-22, 2009. Available at http://www.abstractsonline.com/viewer/ viewAbstract.asp?CKey={A98A01B0-1623-4F71-99C7-FCE19F299C1F}&MKey= {D007B270-E8F6-492D-803B-7582CE7A0988}&AKey={728BCE9C-121B-46B9-A8EE- DC51FDFC6C15}&SKey={CCA05FCE-642E-4E26-AD12-29C831335BE1 }. Accessed 28 July 2010
61. Ossovskaya V, Alvares C, Kaldjian E, Sherman B (2007) The PARP1 gene is over-expressed in triple negative breast cancer (Abstract no. P57) EJC Supplements 5(8): 31. Available at http://www.sciencedirect.com/science?-ob= ArticleURL&-udi=B75GT-4RNTY81-2S&-user=10&-coverDate= 11%2F30%2F2007&-alid=1018721483&-rdoc=5&-fmt=high&-orig= &-cdi=13103&-sort=r&-docanchor=&view=c&-ct=5&-acct= C000050221&-version=1&-urlVersion=0&-userid=10&md5= a0fa3dfd4f586b560109e6ae1bc0f7ff. Accessed 29 July 2010
62. A Tutt M Robson JE Garber SM Domchek MW Audeh JN Weitzel M Friedlander B Arun N Loman RK Schmutzler A Wardley G Mitchell H Earl M Wickens J Carmichael 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235 244 1:CAS:528:DC%2BC3cXpt1KktLc%3D 10.1016/S0140-6736(10)60892-6 20609467
63. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, Macpherson E, Oza AM (2010) Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer (Abstract no. 3002). Presented at the Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL
64. Dent R, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Kemsley K, Carmichael J (2010) Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial (Abstract no. 1018). Presented at the Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL
65. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE (2010) A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer (Abstract no. 1019). Presented at the Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL
66. SL Edwards R Brough CJ Lord R Natrajan R Vatcheva DA Levine J Boyd JS Reis-Filho A Ashworth 2008 Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 1111 1116 1:CAS:528:DC%2BD1cXisFWjtrw%3D 10.1038/nature06548 18264088 (Pubitemid 351317441)
67. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 1:CAS:528: DC%2BD1cXisVOnsg%3D%3D 10.1056/NEJMoa072113 18160686
68. Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL, Gelman R, Winer EP, Garber JE (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy (Abstract no. 551). J Clin Oncol 27(15). Available at http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=65&abstractID=34135. Accessed 29 July 2010
69. HJ Burstein AD Elias HS Rugo MA Cobleigh AC Wolff PD Eisenberg M Lehman BJ Adams CL Bello SE DePrimo CM Baum KD Miller 2008 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 1810 1816 1:CAS:528:DC%2BD1cXmsFemsb8%3D 10.1200/JCO.2007.14.5375 18347007
70. LA Carey HS Rugo PK Marcom W Irvin Jr M Ferraro E Burrows X He CM Perou EP Winer 2008 TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (Abstract no. 1009) J Clin Oncol 26 15 43s
71. C Twelves JM Trigo R Jones F De Rosa A Rakhit S Fettner T Wright J Baselga 2008 Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study Eur J Cancer 44 419 426 1:CAS:528:DC%2BD1cXhtl2isLY%3D 10.1016/j.ejca.2007.12.011 18249110